A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

NCT04718376 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

56

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor has adjusted its R\&D strategy.

Conditions

Platinum-resistant Ovarian Cancer

Interventions

DRUG: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.